http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2537063-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f5ef0e68a190669a8aea84eb19c83ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aaacf277d1ca555b6a99ad72dec179b3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422 |
| filingDate | 2008-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2eb6b0fe7f39f6241e72dd0c54e427d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bc747ef3d87ca19d83980be08e60850 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bdbdd4fa55407e2b7b9c5e0de5ca5fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5d2cec72790e61960a8fea90a601a87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e86b47d0eb2c644e7fab3da870f113d |
| publicationDate | 2015-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2537063-T3 |
| titleOfInvention | Improved pharmaceutical composition containing a calcium channel dihydropyridine antagonist and method for preparing it |
| abstract | A process for the preparation of a solid dosage form for oral administration such as a tablet, capsule or sachet containing Lercanidipine or a pharmaceutically acceptable salt thereof as an active ingredient and an effective amount of colloidal silicon dioxide, to enhance the bioavailability, comprising: - dissolving the total amount of said active ingredient, a portion of the total amount of said colloidal silicon dioxide and a binder in water / EtOH solvent; - adding to the solution formed the remaining portion of the colloidal silicon dioxide and an optional excipient such as a diluent, a binder, a disintegrant, a slider, a lubricant and wet granulation; - dissolving a wetting agent such as Poloxamer in a small amount of water / EtOH solvent and kneading with the first solution; - dry the moistened dough; - Sift the dry mass and add to the sieved mixture the total amounts of at least one optional excipient such as a binder, a diluent, a disintegrant, a lubricant and / or a slider and mix until uniform, and - formulate the mixture resulting in a solid dosage form, either by compression in a desired tablet form or by filling capsules or sachets. |
| priorityDate | 2007-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 75.